DiaSorin receives HIV-1 rights from Dade Behring

DiaSorin has received rights to market and develop immunoassays for the detection of HIV, it has emerged.

Dade Behring and Roche Diagnostics have granted limited rights to the firm to work towards improved detection of HIV-1 group O.

According to Dade Behring, this allows for a wider variety of HIV types to be analysed and reduces the likelihood of an inaccurate test result.

"This sublicence granted by Dade Behring and Roche Diagnostics, coupled with our expertise of being a pure play global immunodiagnostics company with competitive flagship technology, will allow us to accelerate the development of more reliable tests for HIV," said DiaSorin general manager and chief executive officer Carlo Rosa.

Meanwhile, Dade Behring chair, president and chief executive officer Jim Reid-Anderson suggested the results of any development programme are likely to be made available to healthcare providers worldwide.

The firm previously revealed it is to provide equipment to healthcare efficiency supplier MedAssets under a three-year deal.